Nelonicline manufacturers
- Nelonicline
-
- $2500.00 / 100mg
-
2026-04-20
- CAS:1026134-63-3
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Nelonicline Basic information |
| Product Name: | Nelonicline | | Synonyms: | Nelonicline;ABT-126;1-Azatricyclo[3.3.1.13,7]decane, 4-[(5-phenyl-1,3,4-thiadiazol-2-yl)oxy]-, stereoisomer;2-(((3R,4r,5S,7s)-1-azaadamantan-4-yl)oxy)-5-phenyl-1,3,4-thiadiazole;Nelonicline（ABT-126） | | CAS: | 1026134-63-3 | | MF: | C17H19N3OS | | MW: | 313.42 | | EINECS: | | | Product Categories: | | | Mol File: | 1026134-63-3.mol |  |
| | Nelonicline Chemical Properties |
| Boiling point | 460.2±55.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 7.78±0.40(Predicted) | | color | White to off-white |
| | Nelonicline Usage And Synthesis |
| Uses | Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (Ki=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease[1][2][3]. | | References | [1] Zhang D, et al. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015;30(14):1901-1911. DOI:10.1002/mds.26453
[2] Haig G, et al. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study. Neuropsychopharmacology. 2016;41(12):2893-2902. DOI:10.1038/npp.2016.101
[3] Gault LM, et al. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimers Res Ther. 2016;8(1):44. Published 2016 Oct 18. DOI:10.1186/s13195-016-0210-1 |
| | Nelonicline Preparation Products And Raw materials |
|